KT&G Announces Shareholder Benefits and Record Sales in 2023

Business by 2FIRSTS.ai
Feb.20.2024
KT&G Announces Shareholder Benefits and Record Sales in 2023
KT&G boosts shareholder value with 2.8 trillion won policy, plans to destroy 3.5 million shares, announces dividends.

According to South Korean media reports on March 16, KT&G Company has decided to further enhance shareholder value by launching a 28 trillion Korean won shareholder return policy and deciding to destroy 3.5 million of its own shares. This 3.25 trillion won destruction is equivalent to 2.6% of the total issued shares. According to the Korea Exchange, KT&G's destruction accounts for 10% of the total amount of self-owned shares destroyed by listed companies that month.

 

According to reports, the board of directors of KT&G has decided to pay a dividend of 4,000 Korean won in 2023. This includes a final half-year dividend of 1,200 Korean won, bringing the total annual dividend to 5,200 Korean won per share, an increase of 200 Korean won from last year. The dividend yield is 5.7%. KT&G held a "Value Day" in November 2023, announcing a new shareholder return policy totaling 28 trillion Korean won to be implemented by 2026 to enhance shareholder value. In 2023, KT&G achieved a record high comprehensive sales revenue of 58.724 trillion Korean won. 

 

Particularly, the overseas cigarette division achieved an annual sales revenue of 11.394 trillion Korean won, breaking a historical record. The combined annual sales revenue of overseas cigarettes, NGP (e-cigarettes), and health foods reached 33.127 trillion Korean won, a 1.1% increase from the previous year. KT&G's goal for this year is to increase comprehensive sales revenue by over 10% and operating profit by over 6%. Sales revenue and operating profit from the three core businesses are expected to increase by over 15% and 31.5% respectively compared to last year.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
Philip Morris International Restructures to Drive Its Smoke-Free Transformation
Philip Morris International Restructures to Drive Its Smoke-Free Transformation
Philip Morris International (PMI) announced a new organizational model effective January 1, 2026, creating two main business units — PMI International and PMI U.S. — to accelerate its smoke-free strategy. The restructuring replaces four regional segments with three: International Smoke-Free, International Combustibles, and U.S., enhancing agility, governance, and long-term growth in reduced-risk products.
Nov.05 by 2FIRSTS.ai
British Museum Ends Long-Running Sponsorship with Japan Tobacco International
British Museum Ends Long-Running Sponsorship with Japan Tobacco International
According to The Guardian, the British Museum has ended its 15-year sponsorship with Japan Tobacco International after government inquiries into whether the deal breached WHO tobacco-control rules. Critics had long opposed the partnership, while the museum said sponsorship remains essential for its financial stability and public access.
Nov.20
Juul’s San Francisco Headquarters May Be Sold as Debt Talks Advance
Juul’s San Francisco Headquarters May Be Sold as Debt Talks Advance
Real estate firm Affinius Capital is in talks to sell the loan tied to Juul’s San Francisco headquarters, with Madison Capital emerging as a potential buyer. If completed, the deal could lead to a change in ownership six years after Juul first acquired the building, signaling continued asset adjustments amid regulatory pressure.
Oct.23
JUUL wins approval after FDA reversal of Marketing Denial Order
JUUL wins approval after FDA reversal of Marketing Denial Order
JUUL's regulatory journey from Marketing Denial Order to approval showcases FDA's evolving approach to e-cigarette oversight.
Nov.03 by 2FIRSTS.ai
Thailand National Health Commission Advances Vape Regulation Aligned with Anti-Drug Agenda
Thailand National Health Commission Advances Vape Regulation Aligned with Anti-Drug Agenda
Thailand’s Deputy Prime Minister Sophon Saram, who chairs the National Health Commission (NHC), presided over a meeting aligning the nation’s e-cigarette control policies with the government’s “Quick Big Win” anti-drug strategy. The session reviewed progress under the National Health Assembly Resolution on Protecting Children and Youth from E-Cigarettes, which includes five key measures on awareness, enforcement, and prevention.
Nov.05 by 2FIRSTS.ai